Speaker Profile

Ph.D., CSO, Rarebase

Chris is a drug hunter with 25+ years of experience in large pharma and biotech. He spent 20 years at Eli Lilly and Co. where he helped bring over 10 molecules into the clinic across multiple therapeutic areas and across both small and large molecule modalities. Prior to leaving Eli Lilly in 2019, Chris was Vice President of Quantitative Biology. Most recently Chris was CSO at Fulcrum Therapeutics, a clinical stage biotech focused on rare diseases, where he was responsible for the full range of drug discovery, translational science and early development activities including building and advancing the company’s preclinical portfolio through Phase 1 clinical trials. He was the scientific lead for FTX-6058 that is currently in phase 1 clinical testing for Sickle Cell Disease. Chris was instrumental in creating multiple business development partnerships and with engaging the investment community to achieve multiple rounds of financing for the company.


Clinical & Research Tools Showcase:
Rarebase, PBC

Rarebase is a precision medicine company dedicated to efficiently discovering potential therapeutic opportunities for people living with rare genetic diseases.

Accelerating a Path Forward for Rare Disease Drug Discovery
Rarebase has built a platform to efficiently discover potential therapies for genetically defined rare diseases.

 Session Abstract – PMWC 2023 Silicon Valley

Showcase Track S2 - January 25 2.45 P.M.-4.00 P.M.,Showcase Track S2 - January 26 1.30 P.M.-4.00 P.M.,Showcase Track S2 - January 27 1.15 P.M.-1.30 P.M.

The PMWC 2023 Clinical & Research Tools Showcase will provide a 15-minute time slot for selected companies in this space. The Clinical & Research Tools is a showcase for innovative technologies that are used for the analysis of genetic variation and function, helping to advance breakthroughs in genetic health, rare disease conditions on individuals of all ages, complex diseases and cancer care. Next-generation sequencing (NGS) and microarray technologies empower rapidly evolving genomic revolution.